MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-12-31.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss
-18,899 -19,417 -15,095
Depreciation and amortization
54 53 40
Stock-based compensation
1,096 1,096 916
Amortization of operating lease right-of-use asset
135 132 129
Non-cash interest expense
-1 -1 3
Accretion on marketable securities
-142 -145 -125
Prepaid expenses and other current assets
-284 -1,777 1,942
Other assets
9 0 37
Operating lease liability
-159 -216 -86
Deferred revenue, net of deferred contract acquisition costs
-284 -239 -225
Accounts payable and accrued expenses
294 3,201 -2,424
Net cash used in operating activities
-17,631 -13,759 -18,846
Purchases of laboratory and other equipment
26 60 65
Sales and maturities of marketable securities
6,000 2,000 8,000
Purchases of marketable securities
5,870 2,034 8,723
Net cash used in investing activities
104 -94 -788
Net proceeds from sale of common stock under open market sale agreement, net of offering costs
2,313 27,928 397
Net proceeds from sale of common stock under 2019 employee stock purchase plan
70 0 161
Issuance of note payable for insurance policy
0 0 1,020
Net proceeds from option exercises
7 --
Repayment of notes payable
278 274 90
Net cash provided by financing activities
2,112 27,654 1,488
Net change in cash and cash equivalents
-15,415 13,801 -18,146
Cash and cash equivalents at beginning of period
62,786 67,131 -
Cash and cash equivalents at end of period
47,371 62,786 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics, Inc. (VTGN)